Jump Financial LLC Buys New Shares in TG Therapeutics, Inc. $TGTX

Key Points

• Jump Financial LLC acquired a new stake in TG Therapeutics, purchasing 49,100 shares valued at nearly $1.94 million.
• Several institutional investors have significantly increased their holdings in TG Therapeutics, with increases reaching up to 398%.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating, setting a target price of $37.00, while the stock has an average target price of $46.25 based on analyst ratings.

Jump Financial LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 49,100 shares of the biopharmaceutical company's stock, valued at approximately $1,936,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TGTX. NewEdge Advisors LLC boosted its holdings in TG Therapeutics by 4,549.7% in the fourth quarter. NewEdge Advisors LLC now owns 6,928 shares of the biopharmaceutical company's stock valued at $209,000 after purchasing an additional 6,779 shares during the period. State of Tennessee Department of Treasury boosted its holdings in TG Therapeutics by 28.4% in the fourth quarter. State of Tennessee Department of Treasury now owns 59,883 shares of the biopharmaceutical company's stock valued at $1,802,000 after purchasing an additional 13,228 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in TG Therapeutics by 264.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 297,101 shares of the biopharmaceutical company's stock valued at $8,944,000 after purchasing an additional 215,601 shares during the period. Voya Investment Management LLC boosted its holdings in TG Therapeutics by 398.0% in the fourth quarter. Voya Investment Management LLC now owns 273,739 shares of the biopharmaceutical company's stock valued at $8,240,000 after purchasing an additional 218,766 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new position in TG Therapeutics in the fourth quarter valued at $290,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Yann Echelard sold 10,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares of the company's stock, valued at $8,452,463.04. The trade was a 4.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.64% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.25.

TG Therapeutics Trading Up 1.0%

TGTX opened at $28.57 on Thursday. TG Therapeutics, Inc. has a one year low of $21.11 and a one year high of $46.48. The company has a market cap of $4.53 billion, a P/E ratio of 77.22 and a beta of 1.95. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The business's 50-day simple moving average is $33.69 and its 200-day simple moving average is $35.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. During the same period last year, the firm earned $0.04 earnings per share. TG Therapeutics's revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.